Comparative Pharmacology
Head-to-head clinical analysis: LEROCHOL versus LOCHOLEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEROCHOL versus LOCHOLEST.
LEROCHOL vs LOCHOLEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
Locholest is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting fecal excretion. This leads to increased hepatic conversion of cholesterol to bile acids, reducing serum LDL cholesterol.
Oral: 10 mg once daily, taken at bedtime without regard to meals.
Initial dose: 10-20 mg orally once daily, taken in the evening. Titrate as tolerated every 4 weeks to a maximum of 80 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Terminal elimination half-life is approximately 19 hours (range 14-47 hours) for patients with normal renal function; accumulation occurs with once-daily dosing.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Primarily fecal (biliary) as unchanged drug; renal excretion <5%.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant